




Searching News Database: Par Pharmaceutical
HSMN NewsFeed - 16 Jun 2021
Pharmaceutical Associates, Inc. appoints Dr. Suketu Sanghvi as Chief Scientific Officer
Pharmaceutical Associates, Inc. appoints Dr. Suketu Sanghvi as Chief Scientific Officer
HSMN NewsFeed - 4 Jan 2021
Endo Launches Authorized Generic Version of Amitiza(R) (lubiprostone) Capsules in the United States
Endo Launches Authorized Generic Version of Amitiza(R) (lubiprostone) Capsules in the United States
HSMN NewsFeed - 28 Jun 2019
Lannett Enters Into Distribution Agreement For Dantrolene Capsules, Commences Product Launch
Lannett Enters Into Distribution Agreement For Dantrolene Capsules, Commences Product Launch
HSMN NewsFeed - 14 May 2018
Aquestive Therapeutics Settles Patent Infringement Case with Par Pharmaceuticals
Aquestive Therapeutics Settles Patent Infringement Case with Par Pharmaceuticals
HSMN NewsFeed - 26 Apr 2018
Endo to Acquire Somerset Therapeutics and Business of Affiliate Wintac Limited
Endo to Acquire Somerset Therapeutics and Business of Affiliate Wintac Limited
HSMN NewsFeed - 20 Apr 2018
Lannett Names Maureen Cavanaugh Senior Vice President And Chief Commercial Operations Officer
Lannett Names Maureen Cavanaugh Senior Vice President And Chief Commercial Operations Officer
HSMN NewsFeed - 2 May 2016
Endo Announces U.S. District Court Ruling Upholding OPANA(R) ER Intellectual Property
Endo Announces U.S. District Court Ruling Upholding OPANA(R) ER Intellectual Property
HSMN NewsFeed - 25 Jan 2016
Vertice Pharma appoints Dr. Indranil Nandi as Vice President, Research & Development
Vertice Pharma appoints Dr. Indranil Nandi as Vice President, Research & Development
HSMN NewsFeed - 12 Nov 2014
Par Pharmaceutical Announces First FDA Approval of Vasostrict(TM) (vasopressin injection, USP)
Par Pharmaceutical Announces First FDA Approval of Vasostrict(TM) (vasopressin injection, USP)
HSMN NewsFeed - 8 May 2014
Acura Pharmaceuticals Announces Settlement of Patent Litigation With Ranbaxy Inc.
Acura Pharmaceuticals Announces Settlement of Patent Litigation With Ranbaxy Inc.
HSMN NewsFeed - 24 Sep 2013
Forest Laboratories, Inc. Files Lawsuits against Several Companies for Infringement of Savella(R) Patents
Forest Laboratories, Inc. Files Lawsuits against Several Companies for Infringement of Savella(R) Patents
HSMN NewsFeed - 22 Aug 2013
Horizon Pharma Announces Settlement of DUEXIS(R) Patent Litigation With Par Pharmaceutical
Horizon Pharma Announces Settlement of DUEXIS(R) Patent Litigation With Par Pharmaceutical
HSMN NewsFeed - 12 Aug 2013
Elite Pharmaceuticals, Inc. Hires Industry Veteran Doug Plassche as Executive Vice President of Operations
Elite Pharmaceuticals, Inc. Hires Industry Veteran Doug Plassche as Executive Vice President of Operations
HSMN NewsFeed - 20 Jan 2012
NovaDel Announces Termination of License Agreements for Ondansetron Oral Spray Product
NovaDel Announces Termination of License Agreements for Ondansetron Oral Spray Product
HSMN NewsFeed - 30 Mar 2011
Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer
Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer
HSMN NewsFeed - 7 Jul 2010
MonoSol Rx Announces FDA Approval of Zuplenz(R) Oral Soluble Film for Treatment of Nausea and Vomiting
MonoSol Rx Announces FDA Approval of Zuplenz(R) Oral Soluble Film for Treatment of Nausea and Vomiting
HSMN NewsFeed - 4 Jun 2010
Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer
Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer
HSMN NewsFeed - 14 Apr 2010
POZEN Enters into Settlement Agreement With Teva Regarding Paragraph IV Patent Litigation
POZEN Enters into Settlement Agreement With Teva Regarding Paragraph IV Patent Litigation
HSMN NewsFeed - 18 Aug 2009
Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS(R)
Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS(R)
HSMN NewsFeed - 12 Jun 2009
Thomas P. Rice Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
Thomas P. Rice Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
HSMN NewsFeed - 10 Jun 2009
Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA
Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA
HSMN NewsFeed - 18 May 2009
AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
HSMN NewsFeed - 14 Oct 2008
Par Pharmaceutical Announces Resizing of Generic Unit to Optimize Strong First-to-File Pipeline
Par Pharmaceutical Announces Resizing of Generic Unit to Optimize Strong First-to-File Pipeline
HSMN NewsFeed - 16 Jul 2008
BioAlliance Pharma suspends the Phase II/III trial of doxorubicin Transdrug(R) in primary liver cancer
BioAlliance Pharma suspends the Phase II/III trial of doxorubicin Transdrug(R) in primary liver cancer
HSMN NewsFeed - 15 Jul 2008
Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
HSMN NewsFeed - 23 Jun 2008
BioAlliance Pharma extends its Loramyc(TM) License to China with NovaMed Pharmaceuticals
BioAlliance Pharma extends its Loramyc(TM) License to China with NovaMed Pharmaceuticals
HSMN NewsFeed - 28 May 2008
Santarus Announces Development Program for New ZEGERID Prescription Product
Santarus Announces Development Program for New ZEGERID Prescription Product
HSMN NewsFeed - 7 May 2008
Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection
Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection
HSMN NewsFeed - 15 Apr 2008
Santarus Provides Termination Notice to Otsuka America Pharmaceutical for ZEGERID Co-Promotion Agreement
Santarus Provides Termination Notice to Otsuka America Pharmaceutical for ZEGERID Co-Promotion Agreement
HSMN NewsFeed - 26 Mar 2008
BioAlliance Pharma Receives Market Approval for Loramyc(R) in Germany, Belgium and Luxemburg
BioAlliance Pharma Receives Market Approval for Loramyc(R) in Germany, Belgium and Luxemburg
HSMN NewsFeed - 15 Jan 2008
Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation
Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation
HSMN NewsFeed - 9 Jan 2008
BioAlliance Pharma Receives Market Approval for Loramyc(R) in the United Kingdom and Denmark
BioAlliance Pharma Receives Market Approval for Loramyc(R) in the United Kingdom and Denmark
HSMN NewsFeed - 31 Oct 2007
GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
HSMN NewsFeed - 7 Aug 2007
Santarus Receives Notice of Paragraph IV Certification Against Patents for ZEGERID Capsules
Santarus Receives Notice of Paragraph IV Certification Against Patents for ZEGERID Capsules
HSMN NewsFeed - 19 Jul 2007
Ortho-McNeil, Inc. Settles Patent Infringement Litigation Against Par/Kali
Ortho-McNeil, Inc. Settles Patent Infringement Litigation Against Par/Kali
HSMN NewsFeed - 19 Jul 2007
Par Pharmaceutical Announces Agreement with Ortho-McNeil to Settle Ultracet(R) Patent Litigation
Par Pharmaceutical Announces Agreement with Ortho-McNeil to Settle Ultracet(R) Patent Litigation
HSMN NewsFeed - 3 Jul 2007
Par Pharmaceutical Licenses U.S. Commercialization Rights to Loramyc(TM) From BioAlliance Pharma
Par Pharmaceutical Licenses U.S. Commercialization Rights to Loramyc(TM) From BioAlliance Pharma
HSMN NewsFeed - 12 Jun 2007
Immtech and Par Enter Licensing Agreement on Pafuramidine for Treatment of Pneumocystis Pneumonia
Immtech and Par Enter Licensing Agreement on Pafuramidine for Treatment of Pneumocystis Pneumonia
HSMN NewsFeed - 7 Jun 2007
Par Pharmaceutical Names Gerard A. Martino EVP and COO, Veronica A. Lubatkin EVP and CFO
Par Pharmaceutical Names Gerard A. Martino EVP and COO, Veronica A. Lubatkin EVP and CFO
HSMN NewsFeed - 8 Mar 2007
Melvin Sharoky Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
Melvin Sharoky Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
HSMN NewsFeed - 26 Dec 2006
Par Pharmaceutical Receives Approval for Ondansetron Orally Disintegrating Tablets
Par Pharmaceutical Receives Approval for Ondansetron Orally Disintegrating Tablets
HSMN NewsFeed - 19 Dec 2006
Reliant Pharmaceuticals Files Patent Infringement Lawsuit Against Par Pharmaceutical
Reliant Pharmaceuticals Files Patent Infringement Lawsuit Against Par Pharmaceutical
HSMN NewsFeed - 13 Nov 2006
Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
HSMN NewsFeed - 26 Sep 2006
Patrick G. LePore Named President and Chief Executive Officer of Par Pharmaceutical Companies, Inc.
Patrick G. LePore Named President and Chief Executive Officer of Par Pharmaceutical Companies, Inc.
HSMN NewsFeed - 13 Sep 2006
Par Pharmaceutical Announces Agreement With Unimed Pharmaceuticals to Settle AndroGel(R) Patent Litigation
Par Pharmaceutical Announces Agreement With Unimed Pharmaceuticals to Settle AndroGel(R) Patent Litigation
HSMN NewsFeed - 30 Jun 2006
Par Pharmaceutical Receives Final Approval to Market Tranylcypromine Sulfate Tablets
Par Pharmaceutical Receives Final Approval to Market Tranylcypromine Sulfate Tablets
HSMN NewsFeed - 30 May 2006
Par Pharmaceutical Receives Final Approval to Market Polyethylene Glycol 3350 for Oral Solution
Par Pharmaceutical Receives Final Approval to Market Polyethylene Glycol 3350 for Oral Solution
HSMN NewsFeed - 16 May 2006
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Additional items found! 75

Members Archive contains
75 additional stories matching:
Par Pharmaceutical
(Password required)
Par Pharmaceutical
(Password required)